Reported 294,881 shares, up 265,831 (915.1%) from the prior quarter.
Reported value 736.1%; share count 915.1% vs. the prior quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|---|
| 2022-03-31 | 3393000 |
| 2022-06-30 | 2780000 |
| 2022-09-30 | 2522000 |
| 2022-12-31 | 2309000 |
| 2023-03-31 | 819000 |
| 2023-06-30 | 968000 |
| 2023-09-30 | 722000 |
| 2023-12-31 | 1380000 |
| 2024-03-31 | 300000 |
| 2024-06-30 | 416000 |
| 2024-09-30 | 636000 |
| 2024-12-31 | 776000 |
| 2025-03-31 | 6488000 |
| 2025-06-30 | 665000 |
| 2025-09-30 | 834000 |
| 2025-12-31 | 1422000 |
| 2026-03-31 | 2187000 |
| 2026-06-30 | 33177000 |
| 2026-09-30 | 31427000 |
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
| Q3 2026 | Reduced | 774,046 | -42,472 (-5.2%) | < 0.01% | $31,427,000 | 2026-11-16 | |
| Q2 2026 | Added | 816,518 | +747,091 (1076.1%) | < 0.01% | $33,177,000 | 2026-08-14 | |
| Q1 2026 | Added | 69,427 | +12,112 (21.1%) | < 0.01% | $2,187,000 | 2026-05-15 | |
| Q4 2025 | Added | 57,315 | +5,929 (11.5%) | < 0.01% | $1,422,000 | 2026-02-17 | |
| Q3 2025 | Added | 51,386 | +704 (1.4%) | < 0.01% | $834,000 | 2025-11-14 | |
| Q2 2025 | Reduced | 50,682 | -244,199 (-82.8%) | < 0.01% | $665,000 | 2025-08-14 | |
| Q1 2025 | Added | 294,881 | +265,831 (915.1%) | < 0.01% | $6,488,000 | 2025-05-14 | |
| Q4 2024 | Added | 29,050 | +5,242 (22.0%) | < 0.01% | $776,000 | 2025-02-14 | |
| Q3 2024 | Added | 23,808 | +722 (3.1%) | < 0.01% | $636,000 | 2024-11-14 | |
| Q2 2024 | Added | 23,086 | +6,662 (40.6%) | < 0.01% | $416,000 | 2024-08-14 | |
| Q1 2024 | Reduced | 16,424 | -109,647 (-87.0%) | < 0.01% | $300,000 | 2024-05-15 | |
| Q4 2023 | Added | 126,071 | +367 (0.3%) | < 0.01% | $1,380,000 | 2024-02-14 | |
| Q3 2023 | Added | 125,704 | +1,024 (0.8%) | < 0.01% | $722,000 | 2023-11-14 | |
| Q2 2023 | Added | 124,680 | +2,110 (1.7%) | < 0.01% | $968,000 | 2023-08-14 | |
| Q1 2023 | Reduced | 122,570 | -135,756 (-52.6%) | < 0.01% | $819,000 | 2023-05-15 | |
| Q4 2022 | Added | 258,326 | +2,088 (0.8%) | < 0.01% | $2,309,000 | 2023-02-14 | |
| Q3 2022 | Reduced | 256,238 | -92,985 (-26.6%) | < 0.01% | $2,522,000 | 2022-11-14 | |
| Q2 2022 | Reduced | 349,223 | -552 (-0.2%) | < 0.01% | $2,780,000 | 2022-08-15 | |
| Q1 2022 | New | 349,775 | +349,775 (0.0%) | < 0.01% | $3,393,000 | 2022-05-16 |
Who else reported the position
231 managers reported EDGEWISE THERAPEUTICS INC for Q1 2025.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | Unchanged | 15,021,721 | 0 | 7.9% | $330,477,862 | 17 qtrs |
| RA CAPITAL MANAGEMENT L P | Unchanged | 8,909,091 | 0 | 3.27% | $196,000,002 | 5 qtrs |
| PERCEPTIVE ADVISORS LLC | Added | 6,547,328 | +3,861,791 | 5.09% | $144,041,216 | 6 qtrs |
| BlackRock Inc | Added | 6,485,008 | +5,993 | < 0.01% | $142,670,176 | 3 qtrs |
| BAKER BROS ADVISORS LP | Unchanged | 6,155,940 | 0 | 1.5% | $135,430,680 | 17 qtrs |
| JANUS HENDERSON GROUP PLC | Added | 5,282,154 | +298,214 | 0.07% | $122,854,879 | 17 qtrs |
| Novo Holdings A S | Added | 5,350,000 | +350,000 | 8.95% | $117,700,000 | 17 qtrs |
| Paradigm Biocapital Advisors LP | Reduced | 4,394,556 | -99,373 | 4.43% | $96,680,232 | 5 qtrs |
| VANGUARD GROUP INC | Reduced | 4,294,404 | -172,445 | < 0.01% | $94,476,888 | 17 qtrs |
| Cormorant Asset Management LP | Added | 4,101,992 | +695,458 | 6.79% | $90,243,824 | 17 qtrs |
Filing details and methodology As reported
- Report period
- March 31, 2025
- Filed
- May 14, 2025
- Filing type
- 13F-HR
- Position type
- COMM STK
Voting authority reported
- Sole
- 294,881
- Shared
- 0
- None
- 0
“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.